Drug intelligence / Profile preview

RESP302

Development stage: Phase 2
Lead developer: 30 Technology
Administration: Inhalation

Overview

RESP302 is an investigational drug being developed by Thirty Respiratory for the treatment of bronchiectasis and cystic fibrosis. It is administered via nebulization and is currently in clinical trials, with a Phase 2 study ongoing as of 2025. The precise mechanism of action for RESP302 remains unknown, but it appears to be related to nitric oxide or sodium nitrite formulations delivered through inhalation. There are no approved indications or known adverse events reported at this time[1][4][7].

Targets

sGC (Soluble Guanylyl Cyclase)

Beyond the preview

Go deeper on RESP302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RESP302.

Explore the full profile